Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amodiaquine for treating malaria.

P Olliaro1, P Mussano

  • 1TDR, World Health Organization, 20, avenue Appia, 1211 Geneva 27, Switzerland. olliaro@who.ch

The Cochrane Database of Systematic Reviews
|June 14, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of mint virus C, a new member of the genus Carlavirus.

Archives of virology·2025
Same author

Evaluation of the therapeutic efficacy of praziquantel against schistosomes in seven countries with ongoing large-scale deworming programs.

International journal for parasitology. Drugs and drug resistance·2020
Same author

Building the capacity of public health programmes to become data rich, information rich and action rich.

Public health action·2018
Same author

Population pharmacokinetics of intravenous artesunate: a pooled analysis of individual data from patients with severe malaria.

CPT: pharmacometrics & systems pharmacology·2014
Same author

Leishmaniasis chemotherapy--challenges and opportunities.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2011
Same author

Hypoxia modulates the effect of dihydroartemisinin on endothelial cells.

Biochemical pharmacology·2011
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Amodiaquine effectively treats uncomplicated malaria, showing better parasite clearance than chloroquine. While sulfadoxine-pyrimethamine was more effective later, amodiaquine remains a viable option, with no increased adverse events observed.

Area of Science:

  • Malariology
  • Infectious Diseases
  • Pharmacology

Background:

  • Amodiaquine is a widely used antimalarial drug.
  • Concerns exist regarding fatal adverse reactions in adults using amodiaquine for malaria prophylaxis.
  • These concerns have prompted discussions about its withdrawal as a first-line malaria treatment.

Purpose of the Study:

  • To compare the efficacy and safety of amodiaquine against chloroquine and sulfadoxine-pyrimethamine for treating uncomplicated Plasmodium falciparum malaria.

Main Methods:

  • A systematic review and meta-analysis of randomized and quasi-randomized controlled trials.
  • Searches conducted across multiple databases including Cochrane, MEDLINE, EMBASE, and LILACS up to February 2003.
  • Data extraction and quality assessment performed independently by two reviewers.

Related Experiment Videos

Main Results:

  • Amodiaquine demonstrated superior parasite clearance compared to chloroquine at days 7 and 14.
  • Sulfadoxine-pyrimethamine showed greater efficacy for parasite clearance by day 28.
  • No significant differences in adverse events were found between amodiaquine, chloroquine, and sulfadoxine-pyrimethamine; reported effects were minor to moderate.

Conclusions:

  • Evidence supports the continued use of amodiaquine for uncomplicated malaria treatment.
  • Local drug resistance patterns must be considered when selecting antimalarial therapy.
  • Ongoing monitoring for adverse events associated with amodiaquine is recommended.